Merz Pharma Group today announced that it has been granted early
termination of the waiting period under the Hart-Scott Rodino Antitrust
Improvements Act of 1976, as amended, by the U.S. Federal Trade
Commission and the U.S. Department of Justice in connection with the
previously announced US$5.45 per share cash tender offer made by Merz
GmbH & Co. KGaA (“Merz”) and its acquisition subsidiary to purchase all
outstanding shares of common stock of BioForm Medical, Inc. (Nasdaq:
BFRM). The tender offer will expire on February 12, 2010 at 12:00
midnight, New York City time, unless extended.